HIV-positive children who were treated with a combination of protease inhibitors lopinavir and ritonavir were less likely to have recurrent malaria than those who received non-nucleoside reverse transcriptase inhibitors, a study found. Researchers looked at more than 170 HIV-positive children in Uganda and noted that the protease inhibitor group had higher blood levels of antimalarial drugs than the NNRTI group. The findings appear in the New England Journal of Medicine.